Skip to main content
SpringerLink
Log in

Prostatakarzinom

  • Chapter
Uroonkologie

Zusammenfassung

Die geschätzte Anzahl der Neuerkrankungen am Prostatakarzinom stieg 1991 in Deutschland auf 16000 und in den USA auf 122000 (American Cancer Society 1991; Hölzel et al. 1991) und hat sich seit 1979 in den USA etwa verdoppelt (geschätzte Neuerkrankungszahl 1979: 64000; Silverberg 1979). Dadurch wurde das Prostatakarzinom in den USA der häufigste maligne Tumor des Mannes, gefolgt von den Karzinomen der Lunge (101000), des Kolons und Rektums (79000) und der Harnblase (37000). Etwa einer von 11 Männern wird damit im Laufe seines Lebens ein Prostatakarzinom entwickeln. Die höchste Inzidenz wird mit 100,2, bezogen auf 100000 schwarze Einwohner, in Alameda County (USA) erreicht, das entspricht einer kumulativen Inzidenz von 12% der 1–74jährigen. Der Häufigkeit nach rangiert das Saarland an 22. Stelle mit einer Inzidenz von 32,9 auf 100000 Einwohner und einer kumulativen Inzidenz von 3,7%. Das Bundesland Hamburg folgt auf Platz 26 mit 28,5 bzw 3,2%. Am seltensten ist das Prostatakarzinom mit 0,8 auf 100 000 Einwohner bzw einer kumulativen Häufigkeit von 0,1% in China (Wilson 1987).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Aagard J, Christensen MM, Madsen PO (1991) Radical prostatectomy versus placebo in early prostatic carcinoma: a veterans administration cooperative study. In: Altwein JE, Faul P, Schneider W (eds) Incidental carcinoma of the prostate. Springer, Berlin Heidelberg New York Tokyo, pp 220–225

    Google Scholar 

  • Ackermann R, Frohmüller HG (1983) Complications and morbidity following radical prostatectomy. World J Urol 1: 62–67

    Google Scholar 

  • Ackermann R, Altwein JE, Faul P (1991) Aktuelle Therapie des Prostatakarzinoms. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Adolfsson, J, Rönström L, Hedlund PO, Löwhagen L. Carstensen J, Tribukait B (1990) The prognostic value of modal deoxyribonucleic acid in low grade, low stage untreated prostate cancer (1990) J Urol 144: 1404–1407

    PubMed  CAS  Google Scholar 

  • Albers DD, Faulkner KK, Cheatham WN et al. (1973) Surgical anatomy of the pubovesical (puboprostatic) ligaments. J Urol 109: 388–392

    PubMed  CAS  Google Scholar 

  • Altwein JE, Jacobi GH (1980) Hormontherapie des Prostatakarzinoms. Urologe A 19: 350–370

    PubMed  CAS  Google Scholar 

  • Altwein JE, Keuler F (1989) Vorbeugung und Behandlung von Komplikationen nach radikaler Prostatektomie. In: Sommerkamp H, Altwein JE (Hrsg) Prostatakarzinom — Spektrum der kurativen Therapie. Karger, Basel, S 215–243

    Google Scholar 

  • Altwein JE, Leitenberger A, Ay R (1984) Wert der Computertomographie und Lymphographie zum Nachweis von pelvinen Lymphknoten-Metastasen beim Prostatakarzinom. Urol Int 39: 178–1833

    PubMed  CAS  Google Scholar 

  • Altwein JE, Jocham D, Schrott KM, Wirth M, Hölzel D (1989) Empfehlungen zur Tumornachsorge ( Prostata ). Bayer Ärztebl 44: 10

    Google Scholar 

  • Altwein JE, Faul P, Schneider W (1991) Incidental carcinoma of the prostate. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • American Cancer Society (1991) Cancer Facts and Figures. Atlanta

    Google Scholar 

  • Andersson L, Edsmyr F, Könyves I (1983) Estramustine and prednimustine. In: PavoneMacaluso M, Smith PH (eds) Cancer of the prostate and kidney. Plenum Press, New York, pp 359–363

    Google Scholar 

  • Andriole GL, Kavoussi LR, Torrence RJ et al. (1988) Transrectal ultrasonography in the diagnosis and staging of carcinoma of the prostate. J Urol 140: 758–760

    PubMed  CAS  Google Scholar 

  • Anfield FJ, Schroeder J, Curreri AR (1962) Five years clinical experience with 5-fluorouracil. JAMA 181: 295–299

    Google Scholar 

  • Armitage TG, Cooper EH, Newling DWW et al. (1988) The value of measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer. Br J Urol 62: 584

    PubMed  CAS  Google Scholar 

  • Auberger T, Zilch HG, Lukas P et al. (1989) Stellenwert der MR-Tomographie in der bildgebenden urologischen Diagnostik. In: Nagel R (Hrsg): Aktuelle Standortbestimmung der konservativen Therapie des Prostatakarzinoms. De Gruyter, Berlin, pp 35–55

    Google Scholar 

  • Ausfeld R, Tscholl R (1985) Die partielle pelvine Ischämie — ein Verfahren zur Verminderung der Blutung bei radikaler Prostato-Vesikulektomie. Akt Urol 16: 24–26

    Google Scholar 

  • Babaian RJ, Camps JL (1991) The role of prostate-specific antigen as part of the diagnostic trial and as a guide when to perform a biopsy. Cancer 68: 2060–2063

    PubMed  CAS  Google Scholar 

  • Babcock JR, Grayhack JT (1979) Morbidity of pelvic lymphadenectomy. Urology 13: 483–486

    PubMed  CAS  Google Scholar 

  • Badalament RA, O’Toole RV, Young DC et al. (1991) DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer. Cancer 67: 3014–3023

    PubMed  CAS  Google Scholar 

  • Bagshaw MA (1980) External radiation therapy of carcinoma of the prostate. Cancer 45: 1912

    PubMed  CAS  Google Scholar 

  • Bagshaw MA (1986) Current conflicts in the management of prostatic cancer. Int J Radiat Oncol Biol Phys 12: 1721

    PubMed  CAS  Google Scholar 

  • Bagshaw MA (1989) Stellenwert der Strahlentherapie in der Behandlung des Prostatakarzinoms. In: Sommerkamp H, Altwein JE (Hrsg) Prostatakarzinom — Spektrum der kurativen Therapie. Karger, Basel, pp 13–40

    Google Scholar 

  • Bagshaw MA, Ray GR (1983) External beam radiation therapy of prostate carcinoma. In: Skinner DG (ed) Urological cancer. Grune Stratton, New York, pp 53–71

    Google Scholar 

  • Bagshaw MA, Ray GR, Cox RS (1985) Radiotherapy of prostatic carcinoma: long or short-term efficacy. Urology [Suppl] 25: 17–23

    CAS  Google Scholar 

  • Bagshaw MA, Cox RS, Ramback JE (1990) Radiation therapy for localized prostate cancer. Urol Clin Am 17: 787–802

    CAS  Google Scholar 

  • Bandhauer K, Senn E (1987) Radikale retropubische Prostatektomie nach transurethraler Resektion. Verh Dtsch Ges Urol 38: 90–91

    Google Scholar 

  • Barrack ER, Tindall DJ (1987) A critical evaluation of the use of androgen receptor assays to predict the androgen responsiveness of prostatic cancer. Prog Clin Biol Res 239: 155–187

    PubMed  CAS  Google Scholar 

  • Bass RB, Barrett DM (1980) Radical retropubic prostatectomy after transurethral resection. J Urol 124: 495–497

    PubMed  Google Scholar 

  • Bastacky SS, Walsh PC, Epstein JI (1991) Needle biopsy associated tumor tracking of adenocarcinoma of the prostate. J Urol 145: 1003–1007

    PubMed  CAS  Google Scholar 

  • Beckert R, Klima M, Altwein JE (1989) Chemotherapie des Prostatakarzinoms unter palliativer Zielsetzung? Urology 28: A24

    Google Scholar 

  • Béland G (1991) Combination of anandron with orchiectomy in treatment of metastatic prostate cancer. Urology 37 [Suppl]: 25–29

    PubMed  Google Scholar 

  • Beneventi FA, Noback GJ (1949) Distribution of the blood vessels of the prostate gland and urinary bladder: application to retropubic prostatectomy. J Urol 62: 663–671

    PubMed  CAS  Google Scholar 

  • Benson RC, Gill GM, Cummings KB (1983) A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma. Sem Oncol 10: 43–45

    Google Scholar 

  • Berger RE, Ireton R (1983) Combined infrapubic and retropubic ligation of the dorsal vein of penis during radical retropubic surgery. J Urol 130: 1107–1109

    PubMed  CAS  Google Scholar 

  • Berry WR, MacDonald RN (1982) Cisplatin, cyclophosphamide, and prednisone therapy for stage D prostatic cancer. Cancer Treat Rep 66: 1403–1404

    PubMed  CAS  Google Scholar 

  • Berry WR, Laszlo J, Cox E, Walker N, Paulson DF (1979) Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 44: 763–775

    PubMed  CAS  Google Scholar 

  • Bertagna C, de Gery A, Hucher M, Francois JP, Zanirato J Efficacy of the combination of anandron with orchidectomy in stage D prostate cancer. Review of seven studies including 1191 patients. Abstract book 1st International Congress of the Dutch Urological Association (NVA) „Progress and controversies in ontological urology III“. Rotterdam, Oct 9–13, p 4

    Google Scholar 

  • Bishop MC, Ansell ID, Taylor MC, Thomas AL (1985) Serial prostatic histology. A valid marker of response to hormone treatment. Br J Urol 57: 453

    PubMed  CAS  Google Scholar 

  • Blum RH (1975) An overview of studies with adriamycin (NSC-123127) in the United States. Cancer Chemother Rep 6 /3: 247–251

    Google Scholar 

  • Blute ML, Zincke H, Farrow GM (1986) Long-term follow-up of young patients with stage A adenocarcinoma of the prostate. J Urol 136: 840–843

    PubMed  CAS  Google Scholar 

  • Bonnand P, Dufour B, Couvelaire R (1977) Les prostatectomies totales et les prostatotrigonectomies „de nécessité“ dans le traitement du cancer prostatique. J Urol Nephrol 77: 185–190

    Google Scholar 

  • Borden EC, Hawkins MJ, Sielaff KM et al. (1988) Clinical and biological effects of recombinant interferon-beta administered intravenously daily in phase I trial. J Interferon Res 8: 357–366

    PubMed  CAS  Google Scholar 

  • Bostwick DG (1989) Prostatic intraepithelial neoplasia (PIN). Urology [Suppl] 34: 16–22

    CAS  Google Scholar 

  • Bostwick DG, Brawer MK (1987) Prostatic intraepithelial neoplasia and early invasion in prostate cancer. Cancer 59: 778–794

    Google Scholar 

  • Bouffioux C (1979) Le cancer de la prostate. Acta Urol Belg 47: 189–470

    PubMed  CAS  Google Scholar 

  • Boxer RJ, Kaufmann JJ, Goodwin WE (1977) Radical prostatectomy for carcinoma of the prostate: 1951–1976. A review of 329 patients. J Urol 117: 208–213

    PubMed  CAS  Google Scholar 

  • Brannen GE, Gomolka DM, Coffey DS (1975) Specificity of cell membrane antigens in prostatic carcinoma. Cancer Chemother Rep 59: 127–130

    PubMed  CAS  Google Scholar 

  • Brawer MK, Lange PH (1989) Prostate-specific antigen: its role in early detection, scanning, and monitoring of prostatic carcinoma. J Endourol 3: 227

    Google Scholar 

  • Brawn PN, Kuhl D, Johnson C et al. (1990) Stage D1 prostatic carcinoma — the histological appearances of nodal metastases and its relationship to survival. Cancer 65: 538–543

    PubMed  CAS  Google Scholar 

  • Brawn PN, Speights VO, Kuhl D et al. (1991) Prostate-specific antigen levels from completely sectioned, clinically benign, whole prostates. Cancer 68: 1592–1599

    PubMed  CAS  Google Scholar 

  • Brendler CB, Isaacs JT, Follansbee AL et al. (1984) The use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate: a preliminary report. J Urol 131: 694–700

    PubMed  CAS  Google Scholar 

  • Bressel M (1989) Radikale retropubische Prostatektomie (RRP). In: Sommerkamp H, Altwein JE (Hrsg) Prostatakarzinom — Spektrum der kurativen Therapie. Karger, Basel, S 146–173

    Google Scholar 

  • Bretan PN, Williams RD (1987) Imaging techniques in the diagnosis and pelvic staging of prostatic cancer. In: Bruce AW, Trachtenberg J (eds) Adenocarcinoma of the prostate. Springer, Berlin Heidelberg New York, pp 83–106

    Google Scholar 

  • Broders AC (1922) Epithelioma of genito-urinary organs. Ann Surg 75: 574–604

    PubMed  CAS  Google Scholar 

  • Budd GT, Osgord B, Barna B et al. (1989) Phase I clinical trial of interleukin 2 and a-interferon toxicity and immunologic effects. Cancer Res 49: 6432–6436

    PubMed  CAS  Google Scholar 

  • Bulbul MA, Ruben RP, Murphy GP (1986) Interferon-beta treatment of metastatic prostate cancer. J Surg Oncol 33: 231

    PubMed  CAS  Google Scholar 

  • Burk K, Schultze-Seemann W, de Riese W, Hanke P, Weber W (1986) Die ambulante zytostatische Therapie des hormonrefraktären Prostata-Carcinoms mit 4-Epirubicin. 38. Kongr Dt Ges f Urologie (Abstractband). Demeter, Gräfelfing, S 176

    Google Scholar 

  • Byar DP (1973) The VACURG studies of cancer of the prostate. Cancer 32: 1126–1130

    PubMed  CAS  Google Scholar 

  • Byar DP, Cone DK (1984) Analysis of prognostic factors for prostatic cancer in the VACURG studies. In. Denis L, Murphy GP, Prout GR, Schröder F (eds) Controlled clinical trials in urologic oncology. Raven Press, New York, pp 147–169

    Google Scholar 

  • Byar DP, Mostofi FK, VA Cooperative Urological Research Group (1972) Carcinoma of the prostate: prognostic evaluation of certain pathological features in 208 radical prostatectomies. Cancer 30: 5–13

    Google Scholar 

  • Byar DP, Corle DK, VACURG (1981) VACURG randomized trial of radical prostatectomy for stages I and II prostate cancer. Urology [Suppl] 17: 7–11

    CAS  Google Scholar 

  • Campbell BW (1958) Total prostatectomy with preliminary ligation of vascular pedicles. J Urol 81: 464–467

    Google Scholar 

  • Campbell JL, Thomley MW, Parsons RL (1963) Complications of radical prostatectomy. J Urol 89: 253–254

    PubMed  CAS  Google Scholar 

  • Cantrell BB, Deklerk DP, Eggleston JC et al. (1981) Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. J Urol 125: 516–520

    PubMed  CAS  Google Scholar 

  • Carroll PR, Narayan P (1988) Treatment options for hormone insensitive or independent prostatic carcinoma. Semin Urol 6: 322–335

    PubMed  CAS  Google Scholar 

  • Carson CC, Zincke H, Utz DC et al. (1980) Radical prostatectomy after radiotherapy of prostatic cancer. J Urol 124: 237–239

    PubMed  Google Scholar 

  • Carter GE, Lieskovsky G, Skinner DG et al. (1989) Results of local and/or systemic adjuvant therapy in the management of pathological stage C or D1 prostate cancer following radical prostatectomy. J Urol 142: 1266–1271

    PubMed  CAS  Google Scholar 

  • Carter HB, Partin AW, Epstein JI et al. (1990) The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. J Urol 144: 1167–1171

    PubMed  CAS  Google Scholar 

  • Carter SK, Wassermann TH (1975) The chemotherapy of urologic cancer. Cancer 36: 729–747

    PubMed  CAS  Google Scholar 

  • Catalona WJ (1980) Yield from routine prostatic needle biopsy in patients more than 50 years old referred for urology evaluation: a preliminary report. J Urol 124: 844–846

    PubMed  CAS  Google Scholar 

  • Catalona WJ (1990) Patient selection for, results of, and impact in tumor resection of potency sparing radical prostatectomy. Urol Clin N Am 17: 819–826

    CAS  Google Scholar 

  • Catalona WJ, Miller DR, Kavoussi LR (1988) Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy. J Urol 140: 540–543

    PubMed  CAS  Google Scholar 

  • Catalona WJ, Ratliff TL, Yuan JJJ (1990) Serum prostate specific antigen as a first line screening test for prostate cancer. J Urol 143: 313A

    Google Scholar 

  • Catalona WJ, Smith SD, Ratliff TL et al. (1991) Measurement of prostate specific antigen as a screening test for prostate cancer. N Engl J Med 324: 1156–1161

    PubMed  CAS  Google Scholar 

  • Chang AYC (1986) Toxicities of human recombinant interferon alpha in 2 patients with advanced prostate carcinoma. J Interferon Res 6: 713–715

    PubMed  CAS  Google Scholar 

  • Chang AY, Fisher HAG, Spiers ASD et al. (1986) Toxicities of human recombinant interferon alpha 2 in patients with advanced prostate cancer. J Interferon Res 6: 713

    PubMed  CAS  Google Scholar 

  • Chisholm GD (1981) Perspectives and prospects. Recent Results Cancer Res 78: 173–184

    PubMed  CAS  Google Scholar 

  • Chlebowski RT, Herstorff R, Sardoff L, Weiner J, Bateman JR (1978) Cyclophosphamide versus the combination of adriamycin, 5-fluorouracil, and cyclophosphamide in the treatment of metastatic prostatic cancer Cancer 42: 2546–2552

    CAS  Google Scholar 

  • Chodak GW, Vogelzang NJ, Caplan RJ et al. (1991) Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. JAMA 265: 618–621

    PubMed  CAS  Google Scholar 

  • Chute R (1954) Radical prostatectomy for cancer. J Urol 71: 347–351

    PubMed  CAS  Google Scholar 

  • Chybowski FM, Larson Keller JJ, Bergstralh EJ et al. (1991) Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate-specific antigen is superior to all other clinical parameters. J Urol 145: 313

    PubMed  CAS  Google Scholar 

  • Citrin DL, Hogen TF (1982) A phase II evaluation of adriamycin and cisplatinum in hormone-resistant prostatic cancer. Cancer 50: 201–206

    PubMed  CAS  Google Scholar 

  • Clark TD (1987) Nuclear roundness factor: a quantitative approach to grading in prostate carcinoma, reliability of needle biopsy tissue and effect of tumor stage on usefulness. Prostate 10: 199–206

    PubMed  CAS  Google Scholar 

  • Cooner EH, Mosley BR, Rutherford CL Jr et al. (1990) Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143: 1146–1154

    PubMed  CAS  Google Scholar 

  • Cooper EH, Armitage TG, Robinson MRG et al. (1990) Prostate specific antigen and the prediction of prognosis in metastatic prostate cancer. Cancer 66: 1025–1028

    PubMed  CAS  Google Scholar 

  • Cooper EH, Robinson MRG, Whelan P et al. (1992) Tumor markers in prostate cancer. Cancer 70: 225–229

    PubMed  CAS  Google Scholar 

  • Correa RJ Jr, Gibbons RP, Cummings KB, Mason JT (1977) Total prostatectomy for stage B carcinoma of the prostate. J Urol 117: 328

    PubMed  Google Scholar 

  • Crawford ED (1989) Derzeitige Konzepte in der Behandlung des fortgeschrittenen Prostatakarzinoms. In: Altwein JE, Bartsch G (Hrsg) Therapie des fortgeschrittenen Prostatakarzinoms. PMI, Frankfurt, S 46–54

    Google Scholar 

  • Crawford ED, Kiker JD (1983) Radical retropubic prostatectomy. J Urol 129: 1145–1148

    PubMed  CAS  Google Scholar 

  • Crawford ED, Eisenberger MA, McLeod DG et al. (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419–424

    PubMed  CAS  Google Scholar 

  • Creagan ET et al. (1988) Recombinant leukocyte A interferon with doxorubicin; a phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma. Cancer 61: 19

    PubMed  CAS  Google Scholar 

  • Culp OS, Meyer JJ (1973) Radical prostatectomy in the treatment of prostatic cancer. Cancer 32: 1113–1118

    PubMed  CAS  Google Scholar 

  • Cutler SJ, Young JL (1975) Third national cancer survey: incidence data. Natl Cancer Inst Monogr 41

    Google Scholar 

  • Dalesio O (1990) Complete androgen blockade in prostate cancer. Organizing an overview. Cancer 66: 1080–1082

    PubMed  CAS  Google Scholar 

  • Dalton DP, Schaeffler AJ, Garnett JE et al. (1989) Radiographic assessment of the vesicourethral anastomosis directing early decatheterization following nerve-sparing radical retropubic prostatectomy. J Urol 141: 79–81

    PubMed  CAS  Google Scholar 

  • De Laney TF Shipley WU, O’Leary MP, Biggs PJ, Prout GR Jr (1986) Preoperative irradiation, lymphadenectomy and 125-iodine implantation for patients with localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 12: 1779

    Google Scholar 

  • DeKernion JN, My H, Kaufman JJ et al. (1985) Results of treatment of patients with stage Dl prostatic carcinoma. Urology 26: 446–451

    PubMed  CAS  Google Scholar 

  • DeKernion JN, Murphy GD, Priore R et al. (1988) Comparison of flutamide and emcyt in hormone-refractory metastatic prostate cancer. Urology 31: 312–317

    CAS  Google Scholar 

  • Denis L (1992) Maximal androgen blockade: an overview Cancer 1993 (im Druck)

    Google Scholar 

  • Denis L, Smith P, Carneiro de Moura JL et al. (1991) Total androgen ablation: European experience. Urol Clin N Am 18: 65–73

    Google Scholar 

  • Deshpande N et al. (1989) Divergent effects of interferons on benign prostatic hyperplasia cells (BPH) in primary culture. J Urol 141: 157

    PubMed  CAS  Google Scholar 

  • DeVere White R, Olsson CA (1981) Androgen receptor in prostate cancer. Urology 17 [Suppl 4]: 24–26

    PubMed  CAS  Google Scholar 

  • DeYoogt HJ, Sucin S, Sylvester R et al. (1989) Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 EORTC trials. J Urol 141: 883–888

    Google Scholar 

  • DeWys WD, Begg CG, Brodosky H, Creech K, Khandekar J (1983) A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response. Prostate 4: 1–11

    PubMed  CAS  Google Scholar 

  • Dexeus F Logothetis CJ, Samuels MC (1985) Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep 69: 885

    PubMed  Google Scholar 

  • Dhom G (1981) Pathologie des Prostata-Carcinoms. Verh Dtsch Ges Urol 32: 9–16

    Google Scholar 

  • Drago JR, Mostofi FK, Lee F (1989) Prostatic intra-epithelial neoplasia: significance and correlation with prostatic specific antigen and transrectal ultrasound. Urology 34 [Suppl]: 2–69

    Google Scholar 

  • Drelichman A, Brwonlee R, Al-Sarraf M (1981) Phase II study of hexamethylmelamine for disseminated prostatic carcinoma. Cancer Clin Trials 4: 309–312

    PubMed  CAS  Google Scholar 

  • Drelichman A, Osborne CK, von Hoff DD (1982) A phase II clinical investigation of dihydroxyanthracenendione (DHAD) in patients with advanced prostatic cancer. Proc Am Soc Clin Oncol 128: 120

    Google Scholar 

  • Eagen R1 Hahn RG, Myers RR (1976) Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer. Cancer Treat Rep 60: 115–117

    Google Scholar 

  • Edsmyr F Esposti PL, Anderson L (1980) Estramustine phosphate therapy in poorly differentiated carcinoma of the prostate. J Urol Nephrol 55 [Suppl]: 135–138

    Google Scholar 

  • Eggleston JC, Walsh PC (1985) Radical prostatectomy with perservation of sexual function: pathological findings in the first 100 cases. J Urol 134: 1146–1148

    PubMed  CAS  Google Scholar 

  • Eisenberger MA, Bezerdjian L, Kalash SA (1987) A critical assessment of the role of chemotherapy for endocrine resistant prostatic carcinoma. Urol Clin N Am 14: 695–706

    CAS  Google Scholar 

  • Elder JS, Jewett HJ, Walsh PC (1982) Radical perineal prostatectomy for clinical stage BZ carcinoma of the prostate. J Urol 127: 704–706

    PubMed  CAS  Google Scholar 

  • Elder JS, Gibbons RP, Correa RJ Jr et al. (1984) Morbidity of radical perineal prostatectomy following transurethral resection of the prostate. J Urol 132: 55–57

    PubMed  CAS  Google Scholar 

  • Ellis WJ, Isaacs JT (1985) Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas. Cancer Res 45: 6041–6050

    PubMed  CAS  Google Scholar 

  • Epstein JI, Walsh PC, Eggleston JC (1986) Prognosis of untreated state Al prostate carcinoma: a study of 94 cases with extended follow-up. J Urol 136: 837–839

    PubMed  CAS  Google Scholar 

  • Epstein JI, Oesterling JE, Walsh PC (1988) The volume and anatomical location of residual tumor in radical prostatectomy specimens removed for stage Al prostate cancer. J Urol 139: 975–979

    PubMed  CAS  Google Scholar 

  • Epstein JI, Cho KR, Quinn BD (1990) Relationship of severe dysplasia to stage A (incidental) adenocarcinoma of the prostate. Cancer 65: 2321–2327

    PubMed  CAS  Google Scholar 

  • Ercole CJ, Lange PH, Mathisen M et al. (1987) Prostate specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 138: 1181

    PubMed  CAS  Google Scholar 

  • Fair WR (1986) Editorial — Hormonal therapy advanced prostatic cancer. J Urol 136: 653–654

    PubMed  CAS  Google Scholar 

  • Faul P (1991) Die klinische Bedeutung der transrektalen Feinnadelbiopsie und zytologischen Diagnose des Prostatakarzinoms. In: Ackermann R, Altwein JE, Faul P (Hrsg) Aktuelle Therapie des Prostatakarzinoms. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Ferro MA (1991) Use of intravenous stilbestrol diphosphonate in patients with prostatic carcinoma refractory to conventional hormonal manipulation. Urol Clin N Am 18: 139–143

    CAS  Google Scholar 

  • Flanagan WE Webster GD, Brown MW et al. (1985) Lumbosacral plexus stretch injury following the use of modified lithotomy position. J Urol 134: 567–568

    PubMed  CAS  Google Scholar 

  • Fossa SD, Miller A (1976) Treatment of advanced carcinoma of the prostate with estramustine phosphate. J Urol 115: 406–408

    PubMed  CAS  Google Scholar 

  • Fossa SD, Fossa J, Aakvaag A (1977) Hormone changes in patients with prostatic carcinoma during treatment with estramustine phosphate. J Urol 118: 1013–1018

    PubMed  CAS  Google Scholar 

  • Fossa SD, Urnes T, Kaalhus O (1987) Weekly low-dose adriamycin in hormone-resistant cancer of the prostate. Scand J Urol Nephrol 21: 13–16

    PubMed  CAS  Google Scholar 

  • Fossa SD, Aaronson N, Calais da Silva F et al. (1989) Quality of life in patients with muscle-infiltrating bladder cancer and hormone-resistent prostate cancer. Eur Urol 16: 335–339

    PubMed  CAS  Google Scholar 

  • Franks LM (1974) Biology of the prostate and its tumors. In: Castro JE (ed) The treatment of prostatic hypertrophy and neoplasia. Medical and Technical Publ., London, pp 1–26

    Google Scholar 

  • Freeman NC, Doolittle C (1991) Elevated prostate markers in metastatic small cell carcinoma of unknown primary. Cancer 68: 1118–1120

    PubMed  CAS  Google Scholar 

  • Frohmüller H (1991) Management planning for incidental carcinoma of the prostate: decision aids, spectrum, complications. In: Altwein JE, Faul P, Schneider W (eds) Incidental carcinoma of the prostate. Springer, Berlin Heidelberg New York, pp 156–162

    Google Scholar 

  • Frohmüller H, Wirth M (1991) Die radikale Prostatektomie. In: Ackermann R, Altwein JE, Faul P (Hrsg) Aktuelle Therapie des Prostatakarzinoms. Springer, Berlin Heidelberg New York Tokyo, S 100–121

    Google Scholar 

  • Frohneberg D, Bleiberg G, Egghart G et al. (1987) Die radikale Salvage-Prostatektomie — eine erweiterte Indikation zur Prostatovesikulektomie. Verh Dtsch Ges Urol 38: 99–100

    Google Scholar 

  • Frühauf JP, Myers CE, Sinha BK (1990) Synergistic activity of suramin with tumor necrosis factor a and doxorubicin on human prostate cancer cell lines. J Natl Cancer Inst 82: 1206–1209

    Google Scholar 

  • Gerber GS, Chodak GW (1990) Digital rectal examination in the early detection of prostate cancer. Urol Clin N Am 17: 739–744

    CAS  Google Scholar 

  • Gervasi LA, Mata J, Easley JD et al. (1989) Prognostic significance of lymph nodal metastases in prostatic cancer. J Urol 142: 332–336

    PubMed  CAS  Google Scholar 

  • Gibbons RP (1987) Prostate cancer chemotherapy. Cancer 60: 586–587

    PubMed  CAS  Google Scholar 

  • Gibbons RP, Correa RJ Jr, Brannen GE, Mason JT (1984) Total prostatectomy for localized prostatic cancer. J Urol 131: 73–75

    PubMed  CAS  Google Scholar 

  • Gil-Vernet JM, Gutierrez de Pozo R, Caretero P et al. (1988) Urogenital diaphragm raising maneuver. J Urol 140: 555–558

    PubMed  CAS  Google Scholar 

  • Gilbertson VA (1971) Cancer of the prostate gland: results of early diagnosis and therapy undertaken for cure of the disease. JAMA 215: 81

    Google Scholar 

  • Gittes RF (1991) Carcinoma of the prostate. N Engl J Med 324: 236

    PubMed  CAS  Google Scholar 

  • Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemother Rep 50: 125–128

    PubMed  CAS  Google Scholar 

  • Gleason DF, Mellinger GT, The Veterans Administration Cooperative Urological Research Group (1974) Prediction of prognosis for prostatic adenocarcinoma and combined histological grading and clinical staging. J Urol 11: 58–64

    Google Scholar 

  • Goldenberg SL, Ajzen SA, Allen GJ et al. (1989) Combined biopsy techniques: an approach to the diagnosis of prostatic malignancy. J Urol 141: 870–872

    PubMed  CAS  Google Scholar 

  • Goldschmidt AJW, Bauer L, Tunn UW (1990) Third-line Therapie des metastasierenden Prostatakarzinoms mit Interferon. Aktuel Onkol 57: 73–82

    Google Scholar 

  • Goldstein D, O’Leary M, Mitchen J et al. (1991) Effects of interferon b ser and transforming growth factor b on prostatic cell lines. J Urol 146: 1173–1177

    PubMed  CAS  Google Scholar 

  • Goodwin WE (1952) Radical prostatectomy after previous prostatic surgery: technical problems encountered in the treatment of prostatic carcinoma. J Am Med Assoc 148: 799–803

    PubMed  CAS  Google Scholar 

  • Göttinger H, Schmiedt E (1979) Staging-Operation und retropubische Prostatektomie beim Prostatakarzinom. Beitr Urol 1: 121–126

    Google Scholar 

  • Graff J, Pastor J, Bertels C, Demetriou D, Schulze H (1990) Erfahrungen mit der Chemotherapie beim metastasierten Prostatakarzinom. Aktuel Urol 21: 1–6

    Google Scholar 

  • Graham SD, Bostwick DG, Hoisaeter A et al. (1992) Panel III. Report of the Committee on staging and pathology. Cancer 70: 359–361

    PubMed  Google Scholar 

  • Grayhack JT, Assimos DG (1983) Prognostic significance of tumor grade and stage in the patient with carcinoma of prostate. Prostate 4: 13–31

    PubMed  CAS  Google Scholar 

  • Greene DR, Taylor SR, Wheeler TM et al. (1991) DNA ploidy analysis of incidental and early clinical cancer. J Urol 145: 399A

    Google Scholar 

  • Griffiths K, Davies P, Eaton CL et al. (1991) Endocrine factors in the initiation diagnosis, and treatment of prostatic cancer. In: Voigt KD, Knobbe C (eds) Endocrine dependent tumors. Raven Press, New York, pp 83–130

    Google Scholar 

  • Grundmann E (1988) Neue Möglichkeiten der Krebsnachsorge. Dtsch Ärztebl 85: 959

    Google Scholar 

  • Grups JW (1988) Langzeitergebnisse der radikalen Prostatektomie. Urologe A 27: 348–351

    PubMed  CAS  Google Scholar 

  • Guinan P, Bush I, Ray V (1980) The accuracy of the rectal examination in the diagnosis of prostatic carcinoma. N Engl J Med 303: 499–503

    PubMed  CAS  Google Scholar 

  • Guinan P, Bhatti R, Ray P (1987) An evaluation of prostate specific antigen in prostatic cancer. J Urol 137: 686–689

    PubMed  CAS  Google Scholar 

  • Haelst-Piesani van C, Richardson RL, Thormean TM et al. (1990) Phase II study of recombinant leukocyte A human interferon-A (IFN-RA) in patients with advanced hormone-resistant prostate cancer. ASCO, May 20–22, Washington

    Google Scholar 

  • Hall BE, Good JW (1962) Treatment of far advanced cancer with 5-fluorouracil used alone and in combination with irradiation: incidence and duration of remission and survival data in 223 patients. Cancer Chemother Rep 16: 369–386

    PubMed  CAS  Google Scholar 

  • Hammerer P, Huland H (1991) Zur Diagnostik des lokalisierten Prostatakarzinoms: Screening und präoperatives Staging. Urologe A 30: 378–386

    PubMed  CAS  Google Scholar 

  • Hammerer P, Sparenberg A, Gonnermann D et al. (1991) Diagnostik von Lymphknotenmetastasen vor radikaler Prostatektomie. Urologe A 30 [Suppl]: A16

    Google Scholar 

  • Hanash KA, Utz DC, Cook EN et al. (1972) Carcinoma of the prostate: a 15-year follow-up. J Urol 107: 450–453

    PubMed  CAS  Google Scholar 

  • Hanks GE (1988) External beam radiation therapy for postate cancer clinically confined to the gland. Urology 33: 21–26

    Google Scholar 

  • Harada M, Mostofi FK, Corle FK, Byar DP, Trump BF (1977) Preliminary studies of histological prognosis in cancer of the prostate. Cancer Treat Rep 61: 223–225

    PubMed  CAS  Google Scholar 

  • Harisiadis L, Veenema RJ, Senyszyn JJ et al. (1978) Carcinoma of the prostate: treatment with external radiotherapy. Cancer 41: 2131

    PubMed  CAS  Google Scholar 

  • Hauri D, Heinzelmann M, Konstatinidis K (1988) Radical prostatectomy in case of prostatic carcinoma: the problem of postoperative urinary incontinence. Int Urol 43: 257–264

    CAS  Google Scholar 

  • Hayward S, Cox S, Mitchell I (1987) The effects of interferons on the activity of alpha-glycerolphosphate dehydrogenase in benign prostatic hyperplasia cells in primary culture. J Urol 138: 648–653

    PubMed  CAS  Google Scholar 

  • Heany JA, Chang HC, Daly JJ et al. (1977) Prognosis of clinically undiagnosed prostatic carcinoma and the influence of endocrine therapy. J Urol 118: 283–287

    Google Scholar 

  • Hedley DW, Friedlander ML, Taylor IW et al. (1983) Method of analysis of cellular DNA content in paraffine embedded pathological material using flow cytrometry. J Histochem Cytochem 31: 1333–1335

    PubMed  CAS  Google Scholar 

  • Herr HW (1982) Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexanitrosourea in the treatment of metastatic pro-static cancer. J Urol 127: 462–465

    PubMed  CAS  Google Scholar 

  • Herr HW (1983) Interstitial radiotherapy for localized cancer of the prostate. Clin Oncol 2: 407–419

    Google Scholar 

  • Heshmat MY, Kovi I, Herson I et al. (1975) Epidemiologic association between gonorrhoea and prostatic carcinoma. Urology 6: 457–460

    PubMed  CAS  Google Scholar 

  • Hetherington JW, Siddall JK, Cooper EH (1988) Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer. Eur Urol 14: 1–5

    PubMed  CAS  Google Scholar 

  • Hinman F (1989) Atlas of Urologie Surgery. Saunders, Philadelphia

    Google Scholar 

  • Hodge KK, McNeal JE, Terris MK et al. (1989 a) Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142: 71–75

    Google Scholar 

  • Hodge KK, McNeal JE, Stamey TA (1989 b) Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 142: 66–70

    Google Scholar 

  • Hölzel D, Altwein JE (1991) Tumoren des Urogenitaltrakts: Klinisch-epidemiologische Fakten. Urologe A 30: 134–138

    PubMed  Google Scholar 

  • Hölzel D, Sauer H, Waal JC (1988) Tumornachsorge-Schemata: Wissensinhalt — Anwendung —Optimierung. Onkologie 11: 202

    PubMed  Google Scholar 

  • Hopper KD, Parker SH, Yakes WF (1991) The biopsy gun. Hospimedica 9: 52–55

    Google Scholar 

  • Horoszewicz JS, Murphy GP (1989) An assessment of the current use of human inter-ferons in the therapy of urological cancers. J Urol 142: 1173–1179

    PubMed  CAS  Google Scholar 

  • Houghton AL, Robinson MRG, Smith PH (1977) Melphalan in advanced prostatic cancer: a pilot study. Cancer Treat Rep 61: 923–924

    PubMed  CAS  Google Scholar 

  • Hovsepian JA, Byar DP, VACURG (1975) Carcinoma of the prostate. Correlation between radiologie quantification of metastases and patient survical. Urology 6: 11–16

    CAS  Google Scholar 

  • Hsu DS, Babaian RI (1983) 5-Fluorouracil, adriamycin, mitomycin-C (FAM) in the treatment of hormonal-resistant stage D adenocarcinoma of the prostate (abstract C-250). Proc Am Soc Clin Oncol 133: C5250

    Google Scholar 

  • Hudson HC, Howland RJ Jr (1972) Radical retropubic prostatectomy for cancer of the prostate. J Urol 108: 944–947

    PubMed  CAS  Google Scholar 

  • Hudson MA, Balmson RR, Catalona WJ (1989) Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142: 1011–1017

    PubMed  CAS  Google Scholar 

  • Huland H (1991) Morphologische Grundlagen zur radikalen Prostatektomie. Urologe A 30: 361–369

    PubMed  CAS  Google Scholar 

  • Humphrey EW, Hymes AC, Ausman RK et al. (1961) An evaluation of actinomycin-D and mitomycin-C in patients with advanced cancer. Surgery 50: 881–885

    PubMed  CAS  Google Scholar 

  • Igel TC, Barrett DM, Segure JW et al. (1987) Perioperative and postoperative complications from bilateral pelvic lymphadenectomy and radical retropubic prostatectomy. J Urol 137: 1189–1191

    PubMed  CAS  Google Scholar 

  • Ihde DC, Bunn PA, Cohen MH, Dunnick NR, Eddy JC, Minna JD (1980) Effective treatment of hormonally unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide: methods of documenting tumor response and progression. Cancer 45: 1300–1310

    PubMed  CAS  Google Scholar 

  • Ihde DC, Bunn PA, Cohen MH (1981) Combination chemotherapy as initial treatment for stage D2 prostatic cancer (abstract 648). Proc Am Assoc Cancer Res 124: 163

    Google Scholar 

  • Isaacs JT (1984) The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 7: 1–7

    Google Scholar 

  • Iversen P, Christensen MG, Friis E et al. (1990 a) A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 66: 1058–1066

    Google Scholar 

  • Iversen P, Sucin S, Sylvester R et al. (1990 b) Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. Cancer 66: 1067–1073

    Google Scholar 

  • Jackson MA, Ahluwalia BS, Herson J et al. (1977) Characterization of prostatic carcinoma among blacks. A continuation report. Cancer Treat Rep 61: 167–172

    PubMed  CAS  Google Scholar 

  • Janssen J et al. (1985) Phase I study of recombinant human interferon alpha 2c in patients with chemotherapy refractory malignancies. Oncology 47 [Suppl 1]: 3

    Google Scholar 

  • Jewett HJ (1975) The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin N Am 2: 105–124

    CAS  Google Scholar 

  • Jewett HJ, Bridge RW, Gray GF Jr, Shelley WM (1968) The palpable nodule of prostate cancer: results 15 years after radical excision. JAMA 203: 403–406

    PubMed  CAS  Google Scholar 

  • Jewett HR (1972) Radical perineal prostatectomy in the treatment of carcinoma of the prostate. In: Scott R Jr (ed) Current controversies in urologic management. Saunders, Philadelphia, pp 82–95

    Google Scholar 

  • Johansson JE, Andersson SO, Beckman KW, Lindgardh G, Zador G (1987) Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate. Urology 29: 55–59

    PubMed  CAS  Google Scholar 

  • Johansson JE, Adami O, Andersson SO et al. (1989) Natural history of localised prostate cancer. A population-based study in 223 untreated patients. Lancet 1: 778–803

    Google Scholar 

  • Johansson JE, Andersson SO, Holmberg L et al. (1991) Prognostic factors in progression-free survival and corrected survival in patients with advanced prostatic cancer: results from a randomized study comprising 150 patients treated with orchiectomy or estrogens. J Urol 146: 1327–1333

    PubMed  CAS  Google Scholar 

  • Johnson DE, Scott WW Gibbons RP, Prout GR, Schmidt JD, Murphy GP (1976) Clinical significance of serum acid phosphatase levels in advanced prostatic carcinoma. Urology 8: 123–126

    PubMed  CAS  Google Scholar 

  • Jones EC (1990) Resection margin status in radical retropubic prostatectomy specimen: relationship to type of operation, tumor size, tumor grade and local tumor extension. J Urol 144: 89–93

    PubMed  CAS  Google Scholar 

  • Jones WG, Fossa SD, Denis L, Coninx P, Glashan RW, de Pauw M (1983) An EORTC phase II study of vindesine in advanced prostate cancer. Eur J Cancer Clin Oncol 19: 583–588

    PubMed  CAS  Google Scholar 

  • Jones WG, Fossa SD, Bono AV, Croles JJ, Stoter G, de Pauw M, Sylvester R, members of the Genito-Urinary Tract Cooperative Group (1986) Mitomycin-C in the treatment of metastatic prostate cancer: report on a EORTC phase II study. World J Urol 4: 182–185

    Google Scholar 

  • Jonsson G, Hogberg B, Nilsson T (1977) Treatment of advanced prostatic carcinoma with estramustine phosphate (Estracyt). Scand J Urol Nephrol 11: 231–238

    PubMed  CAS  Google Scholar 

  • Jordan WP, Blackard CE, Byar DP (1977) Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 70: 1411–1413

    PubMed  Google Scholar 

  • Kabalin JN, Hodge KK, McNeal JE et al. (1989) Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol 142: 326

    PubMed  CAS  Google Scholar 

  • Kaplan ID, Bagshaw MA, Cox CA et al. (1991) Radiotherapy for incidental adenocarci -noma of the prostate. In: Altwein JE, Faul P, Schneider W (eds) Incidental carcinoma of the prostate. Springer, Berlin Heidelberg New York Tokyo, pp 167–178

    Google Scholar 

  • Karnofsky DA, Abelman WH, Craver LF, Burchenal JH (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1: 634–656

    Google Scholar 

  • Kasimis BS, Moran EM, Miller JB (1983) Treatment of hormone-resistant metastatic cancer of the prostate with 5-fluorouracil, doxorubicin and mitomycin-C (FAM): a preliminary report. Cancer Treat Rep 67: 937–939

    PubMed  CAS  Google Scholar 

  • Kasimis BS, Miller BJ, Kaneshiro CA, Forbes KA, Moran EM, Metter GE (1985) Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin-C (FAM) in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial. J Clin Oncol 3: 385–392

    PubMed  CAS  Google Scholar 

  • Kennealey GT, Marsh JC, Walsh PA (1978) Treatment of advanced carcinoma of the prostate with estramustine and 5-fluorouracil (5-FU) (abstract C-351). Proc Am Soc Clin Oncol 111: 394

    Google Scholar 

  • Keuler FU, Leitenberger A, Altwein JE (1990) Ist die Verschiebung der Altersbegrenzung der radikalen Prostatektomie gerechtfertigt? Aktuel Urol 21: 245–250

    Google Scholar 

  • Khan AU, Tomera FM, Rife CC (1979) Reevaluation of vest technique of vesicourethral reconstruction in radical retropubic prostatectomy. Urology 13: 149–152

    PubMed  CAS  Google Scholar 

  • Killian GS, Yang N, Emrich LJ et al. (1985) Prognostic importance of prostate-specific antigen for monitoring patients with stage B2 to Dl prostate cancer. Cancer Res 45: 886

    PubMed  CAS  Google Scholar 

  • Kleinhans G (1989) DNS-Impulszytophotometrie in der urologischen Onkologie. Klin Exp Urol 21: 1–146

    Google Scholar 

  • Kleinschmidt K, Vieweg J, Gottfried HW et al. (1991) Intra-und postoperative Morbidität der radikalen Prostatektomie. Urologe A 30: 387–393

    PubMed  CAS  Google Scholar 

  • Knabbe C, Kellner U, Voigt KD (1991) Growth factors in human prostate cancer cells: implications for an improved treatment of prostate cancer. J Steroid Biochem Molec Biol 40: 185–192

    PubMed  CAS  Google Scholar 

  • Kofman S, Eisenstein R (1963) Mithramycin in the treatment of disseminated cancer. Cancer Chemother Rep 32: 77–96

    PubMed  CAS  Google Scholar 

  • Kontturi M, Sotarauta M, Tammela T, Lukkarinen O, Romppainen W (1988) Sequentially alternating hormone chemotherapy with high-dose medroxyprogesterone acetate and low-dose epirubicin for the treatment of hormone-resistant metastatic prostatic cancer. Eur Urol 15: 43–47

    PubMed  CAS  Google Scholar 

  • Kopecky AA, Laskowski TZ, Scott R Jr (1970) Radical retropubic prostatectomy in the treatment of prostatic carcinoma. J Urol 103: 641–644

    PubMed  CAS  Google Scholar 

  • Kotake T, Miki 1 Akaza H et al. (1991) Effect of recombinant granulocyte colony-stimulating factor (RG-CSF) on chemotherapy-induced neutropenia in patients with urogenital cancer. Cancer Chemother Pharmacol 27: 253–257

    Google Scholar 

  • Koutsilieris M, Tolls G (1985) Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin or orchidectomy: classification of variables associated with disease outcome. Prostate 7: 31

    PubMed  CAS  Google Scholar 

  • Kozlowski JM, Ellis WJ, Grayhack JT (1991) Advanced prostatic carcinoma. Early versus late endocrine therapy. Urol Clin N Am 18: 15–24

    CAS  Google Scholar 

  • Kramolowsky EV (1988) The value of testosterone deprivation in stage D1 prostatic carcinoma. J Urol 139: 1242

    PubMed  CAS  Google Scholar 

  • Kröpfl D, Krause R, Hartung R (1988) A method to avoid lymphoceles in heparinised patients. J Urol 139: 168

    Google Scholar 

  • Kühn MW, Weißbach L (1990) Primary therapy of metastasized carcinoma of the prostate with Zoladex versus Estracyt — preliminary report. In: Murphy G, Khoury S, Chatelain C, Denis L (eds) Recent advances in urological cancers — diagnosis and treatment. American Cancer Society, Atlanta (USA), pp 86–89

    Google Scholar 

  • Kuss R, Khoury S, Richard F, Fourcade F, Franz P, Capelle JP (1980) Estramustine phosphate in the treatment of advanced prostatic cancer. Br J Urol 52: 29–33

    PubMed  CAS  Google Scholar 

  • Kvols LK, Eagan RT, Myers RP (1977) Evaluation of…, ICRF-159 and hydroxyurea in metastatic prostate cancer: a preliminary report. Cancer Treat Rep 61: 311–312

    PubMed  CAS  Google Scholar 

  • La Rocca RV Cooper MR, Uhrich M et al. (1991) Use of suramin in treatment of prostatic carcinoma refractory to conventional manipulation. Urol Clin N Am 18: 123–129

    Google Scholar 

  • Labrie F Dupont A, Bélanger A et al. (1983) New approach in the treatment of prostate cancer: complete instead of only partial withdrawal of androgens. Prostate 4: 579–584

    PubMed  CAS  Google Scholar 

  • Lange PH, Reddy PK (1987) Technical nuances and surgical results of radical retropubic prostatectomy in 150 patients. J Urol 138: 348–352

    PubMed  CAS  Google Scholar 

  • Lange PH, Moon TD, Narayan P et al. (1986) Radiation therapy as adjuvant treatment after radical prostatectomy: patient tolerance and preliminary results. J Urol 136: 45–49

    PubMed  CAS  Google Scholar 

  • Lange PH, Ercole CJ, Lightner DJ et al. (1989) The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 141: 873

    PubMed  CAS  Google Scholar 

  • Leach GE, Yip C, Donovan BJ (1987) Post-prostatectomy incontinence: the influence of bladder dysfunction. J Urol 138: 574–578

    PubMed  CAS  Google Scholar 

  • Lee F Topr-Pedersen ST, Carrol JT et al. (1989 a) Use of transrectal ultrasound and prostate-specific antigen in diagnosis of prostatic intraepithelial neoplasia. Urology [Suppl] 24: 4–8

    Google Scholar 

  • Lee F, Torp-Pedersen ST, Littrup Pt et al. (1989 b) Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination and prostate specific antigen. Radiology 170: 29–32

    Google Scholar 

  • Lee F Siders DB, Torp-Pedersen, Kirscht JL, McHugh TA, Mitchel AE (1991) Prostate cancer: transrectal ultrasound and pathology comparison. Cancer 67: 1132–1142

    PubMed  CAS  Google Scholar 

  • Lehman TH, Kirchheim D, Braun G et al. (1968) An evaluation of radical prostatectomy for incidentally diagnosed carcinoma of the prostate. J Urol 99: 646–650

    PubMed  CAS  Google Scholar 

  • Leistenschneider W, Nagel R (1980) Estracyt therapy of advanced prostatic cancer with special reference to control of therapy with cytology and DNA cytophotometry. Eur Urol 6: 111–115

    PubMed  CAS  Google Scholar 

  • Leistenschneider W, Nagel R (1984) Praxis der Prostatazytologie. Springer, Berlin Heidelberg New York, pp 82–83

    Google Scholar 

  • Leitenberger A, Altwein JE (1990) Efficacy and discriminative ability of prostate-specific antigen as a tumor marker. Eur Urol 17: 12–16

    PubMed  CAS  Google Scholar 

  • Leitenberger A, Altwein JE (1989) Übersicht über die biologischen Grundlagen der Hormontherapie des Prostatakarzinoms. Aktuel Urol 20: 57–66

    Google Scholar 

  • Leitenberger A, Schneider W, Altwein JE (1991) Do serial PSA determinations offer the best insight into treatment behaviour of advanced prostatic cancer? A pilot study of 130 patients. J Urol 145: 384A

    Google Scholar 

  • Lerner HJ, Mallory TR (1977) Hydroxyurea in stage D carcinoma of prostate. Urology 10: 35–38

    PubMed  CAS  Google Scholar 

  • Li TS, Beling CG (1973) Isolation and characterization of two specific antigens of human seminal plasma. Fertil Steril 24: 134

    PubMed  CAS  Google Scholar 

  • Libertino JA (1988) Complications of urologic surgery. Saunders, Philadelphia

    Google Scholar 

  • Lightner DJ, Lange PH, Reddy PK, Moore L (1990) Prostate specific antigen and local recurrence after radical prostatectomy. J Urol 144: 921–926

    PubMed  CAS  Google Scholar 

  • Lindner A, DeKernion JB, Smith RB et al. (1983) Risk of urinary incontinence following radical prostatectomy. J Urol 129: 1007–1008

    PubMed  CAS  Google Scholar 

  • Liu S, Ewing MW, Anglard P et al. (1991) The effect of suramin, tumor necrosis factor and interferon a on human prostatic carcinoma. J Urol 145: 389–392

    PubMed  CAS  Google Scholar 

  • Livne PM, Huben RP, Wolf RM et al. (1986) Early complications of combined pelvic lymphadenectomy versus lymphadenectomy alone. Prostate 8: 313–318

    PubMed  CAS  Google Scholar 

  • Lloyd RE, Jones SE, Salmon SE, Durie BGM, McMahon CJ (1976) Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: a phase II trial. Cancer Treat Rep 60: 77–83

    PubMed  CAS  Google Scholar 

  • Loening SA, Scott WW, DeKernion JP et al. (1981) A comparison of hydroxyurea, methyl-chloroethyl-chlorohexyl-nitrosourea and cyclophosphamide in patients with advanced prostate canser. J Urol 125: 812–816

    PubMed  CAS  Google Scholar 

  • Loening SA, Beckley S, Brady MF et al. (1983) Comparison of estramustine phosphate, methotrexate, and cisplatinum in patients with advanced hormone-refractory prostate cancer. J Urol 129: 1001–1006

    PubMed  CAS  Google Scholar 

  • Logothetis CJ, Samuels ML, von Eschenbach AC, Trindade A, Ogden S, Grant C, Johnson DE (1983) Doxorubicin, mitomycin-C and 5-fluorouracil (DMF) in the treatment of metastatic hormone-refractory adenocarcinoma of the prostate with a note on the staging of metastatic prostate cancer. J Clin Oncol 1: 368–378

    PubMed  CAS  Google Scholar 

  • Logothetis CJ, Hossan E, Dexeus FH, Sella A, Amato RJ, Killoum RG (1990) Primary combined chemotherapy and hormonal therapy for the treatment of patients with advanced metastatic adenocarcinoma of the prostate. J Urol 143: 309A

    Google Scholar 

  • Lowe BA, Listrom MB (1988) Incidental carcinoma of the prostate: an analysis of the predictors of progression. J Urol 140: 1340–1344

    PubMed  CAS  Google Scholar 

  • Lue TF, Zeineh SJ, Schmidt RA et al. (1984) Neuroanatomy of penile erection: its relevance to iatrogenic impotence. J Urol 131: 273–280

    PubMed  CAS  Google Scholar 

  • Lundberg S, Carstensen J, Rundquist I (1987) DNA flow cytometry and histopathological grading of paraffin-embedded prostate biopsy specimens in a survival study. Cancer Res 47: 1973–1980

    PubMed  CAS  Google Scholar 

  • Lynch HT Larsen AL, Magnuson CW et al. (1966) Prostate carcinoma and multiple primary malignancies; study of a family and 109 consecutive prostate cancer patients. Cancer 19: 1891–1897

    PubMed  CAS  Google Scholar 

  • Mador DR, Huben RP, Wajsman Z et al. (1985) Salvage surgery following radical radiotherapy for adenocarcinoma of the prostate. J Urol 133: 58–60

    PubMed  CAS  Google Scholar 

  • Magnusson A, Fritjofsson A, Norlén BJ et al. (1988) The value of computed tomography and ultrasound in assessment of pelvic lymph node metastases in patients with clinically locally confined carcinoma of the prostate. Scand J Urol Nephrol 22: 7–10

    PubMed  CAS  Google Scholar 

  • Marcus MD, Andriole GL, Coplen DE, Catalona WJ (1990) Detection of prostate cancer (CaP) by digital rectal examination (DRE), prostate-specific antigen (PSA), and trans-rectal ultrasonography (TRUS). J Urol 143: 313A

    Google Scholar 

  • McCullough DL, McLaughlin AP, Gittes RF (1977) Morbidity of pelvic lymphadenectomy and radical prostatectomy for prostatic cancer. J Urol 117: 206–207

    PubMed  CAS  Google Scholar 

  • McDuffie RW, Blundon KE (1978) Radical retropubic prostatectomy: 59 cases. J Urol 119: 514–516

    PubMed  Google Scholar 

  • McLeod DG, Crawford ED, Blumenstein BA et al. (1992) Controversies in the treatment of metastatic prostate cancer. Cancer 70: 324–328

    PubMed  CAS  Google Scholar 

  • McNeal JE, Kindrachuk RA, Freiha FS et al. (1986) Patterns of progression in prostate cancer. Lancet 1: 60–63

    PubMed  CAS  Google Scholar 

  • Medenica RD, Slack N (1985 a) Clinical results of leukocyte interferon-induced tumor regression in resistant human metastatic cancer resistant to chemotherapy and/or radiotherapy-pulse therapy schedule. Cancer Drug Deliv 2: 53–76

    Google Scholar 

  • Medenica RD, Slack N (1985 b) Immunomodulatory activity of human leucocyte interferon in cancer patients: results obtained during pulse therapy schedule. Cancer Drug Deliv 2: 91–118

    Google Scholar 

  • Meikle AW, Smith JA, West DW (1985) Familial factors affecting prostate cancer risk and plasma sex steroid levels. Prostate 6: 121–128

    PubMed  CAS  Google Scholar 

  • Mellin P (1973) Prostatakarzinom. In: Alken CE, Staehler W (Hrsg) Klinische Urologie. Thieme, Stuttgart, S 362–371

    Google Scholar 

  • Mellinger GT, Gleason D, Bailar J (1967) The histology and prognosis of prostatic cancer. J Urol 97: 331–337

    PubMed  CAS  Google Scholar 

  • Merrick MV, Ding CL, Chisholm GG, Elton RA (1985) Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate. Br J Urol 57: 795

    Google Scholar 

  • Merrin CE (1978) Treatment of advanced carcinoma of the prostate (stage D) with infusion of cis-diamine-dichloroplatinum (II NSC-119875): a pilot study. J Urol 119: 522–524

    PubMed  CAS  Google Scholar 

  • Merrin CE (1979) Treatment of genitourinary tumors with cis-dichlorodiamine-platinum (II): experience in 250 patients. Cancer Treat Rep 63: 1579–1589

    PubMed  CAS  Google Scholar 

  • Merrin CE, Etra W, Wajsman Z, Baumgartner G, Murphy GP (1976) Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide, and adriamycin. J Urol 115: 86–88

    PubMed  CAS  Google Scholar 

  • Middleton AW Jr (1987) Radical prostatectomy of carcinoma in men more than 69 years old. J Urol 138: 185–188

    Google Scholar 

  • Miller J, Horsfall DF, Marshall VR et al. (1991) The prognostic value of DNA flow cytometric analysis in stage D2 prostate carcinoma. J Urol 145: 1192–1196

    PubMed  CAS  Google Scholar 

  • Mittlemen A, Shukla SK, Murphy GP (1976) Extended therapy of stage D carcinoma of the prostate with oral estramustine phosphate. J Urol 115: 403–412

    Google Scholar 

  • Monfette G, Dupont A, Labrie F et al. (1991) Multiple advantages before and after radical prostatectomy with combined endocrine therapy. In: Altwein JE, Faul P, Schneider W (eds) Incidental carcinoma of the prostate. Springer, Berlin Heidelberg New York Tokyo, pp 246–253

    Google Scholar 

  • Montle JE (1990) Significance and treatment of positive margins or seminal vesical invasion after radical prostatectomy. Urol Clin N Am 17: 803–812

    Google Scholar 

  • Moore GE, Bross IDJ, Ausman R et al. (1968) Effects of 5-fluorouracil (NSC-19893) in 389 patients with cancer: Eastern Clinical Drug Evaluation Program. Cancer Chemother Rep 52: 641–653

    PubMed  CAS  Google Scholar 

  • Moore MR, Troner MB, DeSimone P, Birch R, Irwin L (1986) Phase II evaluation of weekly cisplatinum in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group trial. Cancer Treat Rep 70: 541–542

    PubMed  CAS  Google Scholar 

  • Moorselaar van RJ, Stratum van P, Borm G et al. (1991) Differential antiproliferative activities of a and 13 interferon and tumor necrosis factor alone or in combination against 2 prostate cancer xenografts transplanted in nude mice. Prostate 18: 331–344

    PubMed  Google Scholar 

  • Morales P, Littman R, Golimbu M 81973) Transpubic surgery: a new approach to difficult operations. J Urol 110: 564–570

    Google Scholar 

  • Morse RM, Spirnak JP, Resnik MI (1988) Iatrogenic colon and rectal injuries associated with urological intervention: report of 14 patients. J Urol 140: 101–103

    PubMed  CAS  Google Scholar 

  • Mostofi FK (1975) Grading of prostate carcinoma. Cancer Chemother Rep Part I, 59: 111–117

    CAS  Google Scholar 

  • Mostofi FK, Davis CJ Jr, Sesterhenn IA (1992) Pathology of carcinoma of the prostate. Cancer 70: 235–253

    PubMed  CAS  Google Scholar 

  • Mostofi FK, Price EB (1973) Tumors of the male genital system. Atlas of tumor pathology. 2nd Ser. Fasc. 8 Armed Forces Institute of Pathology. Washington DC

    Google Scholar 

  • Mostofi FK, Sesterhenn IA, Davis CJ Jr (1976) Problems in pathologic diagnosis of prostatic carcinoma. Semin Oncol 3: 161–169

    PubMed  CAS  Google Scholar 

  • Mostofi FK, Davis CJ Jr, Sesterhenn IA (1989) Malignant change in hyperplastic prostates: the AFIP experience. Urology 34 [Suppl]: 49–51

    PubMed  CAS  Google Scholar 

  • Müller HA, Ackermann R, Frohmüller HGW (1980) The value of perineal punch biopsy in estimating the histological grade of carcinoma of the prostate. The Prostate 1: 303–309

    PubMed  Google Scholar 

  • Mundi AR (1982) A pilot study of hydroxyurea in hormone „escaped“ metastatic carcinoma of the prostate. Br J Urol 54: 20–25

    Google Scholar 

  • Murphy GP, Gibbons RP, Johnson DE et al. (1977) A comparison of estramustine phosphate and streptozotocin in patients with prostatic carcinoma who had extensive irradiation. J Urol 118: 288–291

    PubMed  CAS  Google Scholar 

  • Murphy GP, Natarajan N, Pontes JE, Schmitz RC, Smart CR, Schmidt JD, Mettlin C (1982) The national survey of prostate cancer in the United States by the American Col-lege of Surgeons. J Urol 127: 928–934

    PubMed  CAS  Google Scholar 

  • Murphy GP, Beckly S, Brady MF et al. (1983) Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51: 1264–1271

    PubMed  CAS  Google Scholar 

  • Murphy GP, Huben RP, Priore R et al. (1986) Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28: 36–40

    PubMed  CAS  Google Scholar 

  • Muss HB, Howard V, Richards F et al. (1981) Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial. Cancer 47: 1949–1954

    PubMed  CAS  Google Scholar 

  • Myers RP, Zincke P, Fleming TR (1983) Hormonal treatment at time of radical prostatectomy for stage Dl prostate cancer. J Urol 130: 99–101

    PubMed  CAS  Google Scholar 

  • Myers RP, Goellner JR, Cahill DR (1987) Prostate shape, external striated urethral sphincter and radical prostatectomy: the apical dissection. J Urol 138: 543–550

    PubMed  CAS  Google Scholar 

  • Nagel R (1974) Das Prostatakarzinom in den verschiedenen Altersgruppen. Aktuel Urol 5: 25–32

    Google Scholar 

  • Narayan P, Jajodia P, Stein R (1991) Core biopsy instrument in the diagnosis of prostate cancer: superior accuracy to fine needle aspiration. J Urol 145: 795–797

    PubMed  CAS  Google Scholar 

  • Natale RB, Yagoda A, Watson RC, Stover DE (1980) Phase II trial of neocarcinostatin in patients with bladder and prostatic cancer. Cancer 45: 2836–2842

    PubMed  CAS  Google Scholar 

  • Nativ O, Myers RP, Farrow GM et al. (1990) Nuclear DNA ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma. J Urol 144: 303–306

    PubMed  CAS  Google Scholar 

  • Neerhut GJ, Wheeler 1 Cantini M et al. (1988) Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate. J Urol 140: 544–549

    Google Scholar 

  • Neri R, Kassem N (1984) Biological and clinical properties of antiandrogens. Prog Cancer Res Ther 31: 507–518

    CAS  Google Scholar 

  • Nesbit RM, Plumb RT (1946) Prostatic carcinoma: follow-up on 795 patients treated prior to endocrine era and comparison of survival rates between these and patients treated by endocrine therapy. Surgery 20: 263–270

    PubMed  CAS  Google Scholar 

  • Newling DWW (1987) The value of reversible androgen suppression as a diagnostic test. Prog Clin Biol Res 243 A: 261–265

    Google Scholar 

  • Newling DWW, McLeod D, Soloway M et al. (1992) Distant disease. Cancer 70: 365–367

    PubMed  CAS  Google Scholar 

  • Nichols R1 Barry JM, Hodges CV (1977) The morbidity of radical prostatectomy for multifocal stage I prostatic adenocarcinoma. J-Urol 117: 83–84

    PubMed  CAS  Google Scholar 

  • Nichols WC, Kvols LK, Richardson RL (1982) A phase II study of aziridinylbenzoqui- none (AZQ) in advanced genitourinary (GU) cancer. Proc Am Soc Clin Oncol 125: 117

    Google Scholar 

  • Niijima T, Ro 22–8181 Oncology Study Group (1985) Clinical efficacy of recombinant human leucocyte A interferon (r IFN-a A) on malignant tumors of the urogenital tract. Jpn J Cancer Chemother 12: 921–927

    Google Scholar 

  • Nilsson T (1980) Estracyt — clinical experiences. Scand J Urol Nephrol 55 [Suppl]: 135–138

    CAS  Google Scholar 

  • Nissen NI, Pajak TF, Leone LA (1980) Clinical trial of VP-16–213 (NSC-141540) IV twice weekly in advanced neoplastic disease: a study by the- Cancer and Leukemia Group B. Cancer 45: 232–235

    PubMed  CAS  Google Scholar 

  • Noble RL (1977) The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 37: 1928–1933

    Google Scholar 

  • O’Bryan RM, Luce JK, Talley RW et al. (1973) Phase II evaluation of adriamycin in human neoplasia. Cancer 32: 1–8

    PubMed  Google Scholar 

  • O’Bryan RM, Baker LH, Gottlieb JE et al. (1977) Phase II evaluation of adriamycin in human neoplasia. Cancer 39: 1940–1948

    PubMed  Google Scholar 

  • O’Donnell PD, Finau BJ (1989) Continence following nerve-sparing radical prostatectomy. J Urol 142: 1227–1228

    PubMed  Google Scholar 

  • O’Donoghue EPN, Constable AR, Sherwood T, Stevenson JJ, Chisholm GD (1978) Bone scanning and plasma phosphatase in carcinoma of the prostate. Br J Urol 50: 172–177

    PubMed  Google Scholar 

  • Oesterling JE (1991) Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907–923

    PubMed  CAS  Google Scholar 

  • Oesterling JE, Chan DW, Epstein JL et al. (1988) Prostate specific antigen in the preoperative and postoperative evaluation of localized prostate cancer treated with radical prostatectomy. J Urol 139: 766–772.

    PubMed  CAS  Google Scholar 

  • Ojeda L, Sharif R, Lee M et al. (1986) Lymphocele formation after extraperineal pelvic lymphadenectomy: possible predisposing factors. J Urol 136: 616–618

    PubMed  CAS  Google Scholar 

  • Olsson CA (1987) Management of localized adenocarcinoma of the prostate. In: Bruce AW, Trachtenberg J (eds) Adenocarcinoma of the prostate. Springer, London, pp 129–144

    Google Scholar 

  • Orava M, Cantrell K, Vikho R (1986) Treatment with preparations of human leucocyte interferon decreases serum testosteron concentrations in men. Int J Cancer 38: 295–296

    PubMed  CAS  Google Scholar 

  • Osborne CK, Drelichman A, Hoff von DD, Crawford DE (1983) Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. Cancer Treat Rep 67: 1133–1135

    PubMed  CAS  Google Scholar 

  • Palken M, Cobb 0E, Warren BH et al. (1990) Prostate cancer: correlation of digital rectal examination, transrectal ultrasound and prostate specific antigen levels with tumor volumes in radical prostatectomy specimens. J Urol 143: 1155–1162

    PubMed  CAS  Google Scholar 

  • Parry WL (1983) Radical perineal prostatovesiculectomy. In: Glenn JF (ed) Urologic surgery. Lippincott, Philadelphia, pp 960–967

    Google Scholar 

  • Partin AW, Carter HB, Chan DW et al. (1990) Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign prostatic hyperplasia. J Urol 143: 474–752

    Google Scholar 

  • Paulson DF (1980) The prognostic role of lymphadenectomy in adenocarcinoma of the prostate. Urol Clin N Am 7: 615–629

    CAS  Google Scholar 

  • Paulson DF (1987) The management of prostatic malignancy. In: DeKernion JB, Paulson DF (eds) Genitourinary cancer management. Lea Febiger, Philadelphia, pp 107–160

    Google Scholar 

  • Paulson DF (1988) Diagnosis of metastatic or locally recurrent prostatic cancer. In: McCullough DL (ed) Difficult diagnosis in urology. Churchill Livingstone, New York, p 277

    Google Scholar 

  • Paulson DF (1989) Editorial Comment, J Urol 142: 74

    Google Scholar 

  • Paulson DF, Berry WR, Cox EB, Walker A, Laszlo J (1979) Treatment of metastatic endocrine unresponsive carcinoma of the prostate gland with multiagent chemotherapy: indicators of response to therapy. J Natl Cancer Inst 53: 615–622

    Google Scholar 

  • Paulson DF, Lin GH, Hinshaw W et al. (1982) Radical surgery versus radiotherapy for stage A2 and stage B adenocarcinoma of the prostate. J Urol 128: 502–505

    PubMed  CAS  Google Scholar 

  • Paulson DF, Robertson JE, Danbert LM et al. (1988) Radical prostatectomy in stage A prostatic adenocarcinoma. J Urol 140: 535–539

    PubMed  CAS  Google Scholar 

  • Pavone-Macaluso M, Lund F, Mulder JF (1980) EORTC protocols in prostatic cancer. Scand J Urol Nephrol 55 [Suppl]: 163–168

    CAS  Google Scholar 

  • Pavone-Macaluso M, de Voogt HJ, Viggiano G et al. (1986) Comparison of diethylstilbestrol, cyproterone acetate and medroxy-progesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the EORTC Urological Group. J Urol 136: 624–631

    PubMed  CAS  Google Scholar 

  • Pearlman CK, Kobashi LI (1972) Frequency of intercourse in man. J Urol 107: 298–301

    PubMed  CAS  Google Scholar 

  • Pedersen KV, Carlson P, Vahrenhorst E et al. (1990) Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. Br Med J 300: 1041–1044

    CAS  Google Scholar 

  • Peehl DM, Wong ST, Stamey TA (1991) Cytostatic effects of suramin on prostate cancer cells cultured from primary tumors. J Urol 145: 624–630

    PubMed  CAS  Google Scholar 

  • Perloff M, Ohnuma T, Holland JF (1977) Adriamycin (ADM) and diaminedichloroplatinum (DDP) in advanced prostatic carcinoma (PC). Proc Am Soc Clin Oncol 99: 333

    Google Scholar 

  • Peter CA, Walsh PC (1985) Blood transfusion and anesthetic practices in radical retropubic prostatectomy. J Urol 134: 81–83

    Google Scholar 

  • Peters PC (1980) Complications of radical prostatectomy and lymphadenectomy. Trans Am Assoc GU Surg 72: 13–15

    Google Scholar 

  • Peters PC (1988) Complications of radical prostatectomy and lymphadenectomy. Urol Clin N Am 15: 219–221

    CAS  Google Scholar 

  • Pilepich MV Zinninger MSN, Johnson RJ et al. (1987) Prognostic significance of nodal involvement in locally advanced (stage C) carcinoma of prostate — RTOG experience. Urology 30: 535

    PubMed  CAS  Google Scholar 

  • Prout GR Jr (1973) Diagnosis and staging of prostatic carcinoma. Cancer 32: 1096–1099

    PubMed  Google Scholar 

  • Qazi R, Khandekar J (1983) Phase II study of cisplatinum for metastatic prostatic carcinoma: an Eastern Cooperative Oncology Group study. Am J Clin Oncol (CCT) 6: 203–205

    CAS  Google Scholar 

  • Rainwater LM, Morgan WR, Klee GG, Zincke H (1990) Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma. Mayo Clin Proc 65: 1118–1126

    PubMed  CAS  Google Scholar 

  • Ray GR, Bagshaw MA, Feiha FS (1984) External beam radiation salvage for residual or recurrent local tumor following radical prostatectomy. J Urol 132: 926–930

    PubMed  CAS  Google Scholar 

  • Reiner WG, Walsh PC (1979) An anatomical approach to the surgical management of the dorsal vein and Santorinis plexus during radical retropubic surgery. J Urol 121: 198–200

    PubMed  CAS  Google Scholar 

  • Reiner WG, Scott WW, Eggleston JC, Walsh PC (1979) Long-term survival after hormonal therapy for stage D prostate cancer. J Urol 122: 183–184

    PubMed  CAS  Google Scholar 

  • Richards D (1989) Imaging the prostate. Clin Radiol 40: 335–336

    Google Scholar 

  • Rifkin MD, Zerhoni EA, Gatsornis CA et al. (1990) Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. N Engl J Med 323: 621–626

    PubMed  CAS  Google Scholar 

  • Rohlfs PL, Flocks RH (1969) Stilbestrol therapy in 100 cases of prostatic carcinoma. J Iowa Med Soc 59: 1096–1101

    Google Scholar 

  • Ross RK, Paganini-Hill A, Henderson B (1983) The etiology of prostate cancer: what does epidemiology suggest? Prostate 4: 333–344

    PubMed  CAS  Google Scholar 

  • Rossof AH, Talley RW, Stephens R et al. (1979) Phase II evaluation of cis-dichloro-diamineplatinum (II) in advanced malignancies of the genitourinary and gynecological organs: a Southwest Oncology Group study. Cancer Treat Rep 63: 1557–1565

    PubMed  CAS  Google Scholar 

  • Rothauge CF, Kranshaar J, Gutschank S et al. (1981) Das Verhalten der Phosphatasen und des karzinoembryonalen Antigens im Serum nach spezifischer Immuntherapie des entgleisten metastasierten Prostatakarzinoms. Helv Clin Acta 57: 453–457

    Google Scholar 

  • Rothauge CF, Kranshaar J, Prinz J (1988) Immuntherapie beim Prostatakarzinom. Therapiewoche 38: 2727–2730

    Google Scholar 

  • Rübben H, Altwein JE (1987) Das fortgeschrittene Prostatakarzinom — Ein therapeutisches Dilemma? Urologe A 26: 7–14

    PubMed  Google Scholar 

  • Rudy DC, Woodside JR, Crawford ED (1984) Urodynamic evaluation of incontinence in patient undergoing modified Campbell radical prostatectomy: a prospective study. J Urol 132: 708–712

    PubMed  CAS  Google Scholar 

  • Sause WT, Richards RS, Plenk HP (1986) Prostatic carcinoma: 5-year follow-up of patients with surgically staged disease undergoing extended field radiation. J Urol 135: 517

    PubMed  CAS  Google Scholar 

  • Schellhammer PF (1988) Radical prostatectomy. Patterns of local failure and survival in 67 patients. Urology 31: 191

    PubMed  CAS  Google Scholar 

  • Schellhammer PF, El-Mandi AM (1990) Local failure and related complications after definitive treatment of carcinoma of the prostate by irradiation or surgery. Urol Clin N Am 17: 835–851

    CAS  Google Scholar 

  • Schellhammer PF Schlossberg SM, El-Mandi AM (1991) Prostate specific antigen levels after definitive irradiation for carcinoma of the prostate. J Urol 145: 1008–1011

    PubMed  CAS  Google Scholar 

  • Scher H, Yagoda A, Watson R, Serber M, Whitmore W (1984) Phase II trial of adria- mycin in bidimensionally measurable prostatic adenocarcinoma. J Urol 131: 1099–1102

    PubMed  CAS  Google Scholar 

  • Scher H, Yagoda A, Ahmed T et al. (1985) Phase II trial of mitognazone in bi-dimen- sionally measurable hormone resistant prostatic carcinoma. J Clin Oncol 3: 224–228

    PubMed  CAS  Google Scholar 

  • Schmidt JD, Gibbons RP, Murphy GP et al. (1990) Chemohormonal treatment: NPCP protocols 900/1000. In: Murphy G, Kousy S, Chatelain C, Denis L (eds) Recent advances in urological cancers — diagnosis and treatment. American Cancer Society, Atlanta/ USA, pp 75–83

    Google Scholar 

  • Schmidt JD (1983) Combination of chemotherapy and hormones in prostatic cancer. In: Pavone-Macaluso M, Smith PM (eds) Cancer of the prostate and the kidney. Plenum, New York, p 397

    Google Scholar 

  • Schmidt JD (1984) Cooperative clinical trials of the National Prostatic Cancer Project: Protocol 900. Prostate 5: 387–399

    PubMed  CAS  Google Scholar 

  • Schmidt JD, Scott WW, Gibbons RP et al. (1979) Comparison or procarbazine, imdiazol-carboxamide, and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. J Urol 121: 185–189

    PubMed  CAS  Google Scholar 

  • Schmitz-Dräger BJ, Ebert T, Miller S et al. (1988) Accuracy of transrectal ultrasonography, computerized tomography in the evaluation of T-category in prostatic carcinoma. J Urol 139: 179A

    Google Scholar 

  • Schröder FH (1988) Current concepts in the management of prostatic cancer. Am J Clin Oncol 11 [Suppl I]: 51–55

    Google Scholar 

  • Schröder FH (1991) Hormonal manipulation of prostate cancer. Too soon for total androgen blockade? Br Med J 303: 1489–1490

    Google Scholar 

  • Schröder FH, Belt E (1975) Carcinoma of the prostate: a study of 213 patients with stage C tumors treated by total perineal prostatectomy. J Urol 114: 257–260

    Google Scholar 

  • Schröder FH, Hop WC, Bloom JH et al. (1985) Grading of prostatic carcinoma. III. Multivariate analysis of prognostic parameters. Prostate 7: 13–20

    Google Scholar 

  • Schrader FH, Cooper EH, Debruyne FMJ et al. (1988) TNM classification of genitourinary tumours 1987 — position of the EORTC genitourinary group. Br J Urol 62: 502–510

    Google Scholar 

  • Schulze H, Willenberg A, Haupt G (1991) Der nukleäre Rundheitsfaktor als prognostischer Parameter beim lokalen Prostatakarzinom. Urologe A 30: 19A

    Google Scholar 

  • Schultze-Seemann W (1990) Kombinationstherapie Interferon und komplette Androgen-Deprivation beim metastasierten Prostatakarzinom. Aktuel Onkol 57: 83–88

    Google Scholar 

  • Scott R, Mutchnik DL, Laskowski TZ et al. (1969) Carcinoma of the prostate in elderly men: incidence, growth characteristics and clinical significance. J Urol 101: 602–607

    PubMed  Google Scholar 

  • Scott WW, Boyd HL (1969) Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: a retrospective study based upon 25 years of experience. J Urol 101: 86–92

    PubMed  CAS  Google Scholar 

  • Sensabaugh GF, Crim D (1978) Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification. J Forens Sci 12: 106–115

    Google Scholar 

  • Servadio C, Mukamel E, Kahan E (1984) Carcinoma of the prostate in Israel: some epdidemiological and therapeutic considerations. Prostate 5: 375

    PubMed  CAS  Google Scholar 

  • Sesterhenn IA, Mostofi FK, Davis CJ Jr (1985) Immunopathology in prostate and bladder tumors. In: Russo J (ed): Immunocytochemistry in tumor diagnosis. Martinus Nijhoff, Boston, pp 337–350

    Google Scholar 

  • Sesterhenn IA, Becker RL, Avallon FA et al. (1991) Image analysis of nucleoli and nucleolar organizing regions in prostate, hyperplasia, intraepithelial neoplasia and pro-static carcinoma. J Urogen Pathol 1: 61–74

    Google Scholar 

  • Shearer RJ (1991) Prostatic specific antigen. Br J Urol 67: 1–5

    PubMed  CAS  Google Scholar 

  • Sica G, Fabbronni L, Dell’Aqua G (1989) Antiproliferative effect of interferons on human prostate carcinoma cell lines. Urol Res 17: 111

    PubMed  CAS  Google Scholar 

  • Siddall JK, Cooper EH, Newling DWW, Robinson MRG, Whelan P (1986) An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate. Eur Urol 12: 123–130

    PubMed  CAS  Google Scholar 

  • Silverberg E (1979) Cancer statistics. CA 29: 6–21

    PubMed  CAS  Google Scholar 

  • Skipper HE (1971) Kinetics of mammary tumor all growth and implications for therapy. Cancer 28: 1479–1499

    PubMed  CAS  Google Scholar 

  • Slack NH (1983) Results of chemotherapy protocols of the USA National Prostatic Cancer Project (NPCP). Clin Oncol 2: 441–459

    Google Scholar 

  • Smalley RV, Bartolucci AA, Hemstreet G, Hester M (1981) A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin, and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. J Urol 125: 191–195

    PubMed  CAS  Google Scholar 

  • Smith AM, Veenema RJ (1972) Management of rectal injury and rectourethral fistulas following radical retropubic prostatectomy. Urology 108: 778–779

    CAS  Google Scholar 

  • Smith JA (1989) Patient selection of radical prostatectomy. Urology 33 [Suppl]:17–20 Smith JA, Cho YH (1990) Management of stage A prostate cancer. Urol Clin N Am 17: 769–777

    Google Scholar 

  • Smith JA, Middleton RG (1987) Methods of definitive local therapy. In: Smith JA, Middleton RG (eds) Clinical management of prostatic cancer. Year Book Medical, Chicago, pp 54–84

    Google Scholar 

  • Smith PH (1990) The case for no initial treatment of localized prostate cancer. Urol Clin N Am 17: 827–834

    CAS  Google Scholar 

  • Smith PH, Suciu S, Robinson MRG et al. (1986) A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the EORTC. J Urol 136: 619–623

    PubMed  CAS  Google Scholar 

  • Smith PH, Bono A, Calais da Silva F et al. (1990 a) Some limitation of the radio-isotope bone scan in patients with metastatic prostate cancer. Cancer 66: 1009–1016

    Google Scholar 

  • Smith PH, Armitage TG, Cooper EH (1990 b) Deferred treatment in localized prostatic cancer. Prog Clin Biol Res 359: 191

    Google Scholar 

  • Smith RB, Skinner DG (eds) (1976) Complications of urologic surgery. Prevention and management. Saunders, Philadelphia

    Google Scholar 

  • Sogani PC, Watson RC, Whitemore WF Jr (1981) Lymphocele after pelvic lymphadenectomy for urologic cancer. Urology 17: 39–43

    PubMed  CAS  Google Scholar 

  • Sökeland J (1974) Erfahrungen mit der radikalen Prostatektomie in Deutschland. Verh Dtsch Ges Urol 25: 353–355

    Google Scholar 

  • Soloway MS, Shippel RM, Ikard M (1979) Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate. J Urol 122: 637–639

    PubMed  CAS  Google Scholar 

  • Soloway MS, DeKernion JB, Gibbons RP et al. (1981) Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced hormone-refractory, previously irradiated carcinoma of the prostate. J Urol 125: 664–667

    PubMed  CAS  Google Scholar 

  • Soloway MS, Beckley S, Brady MF et al. (1983) A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone-refractory prostate cancer who had extensive irradiation to the pelvis or lumbosacral area. J Urol 129: 56–61

    PubMed  CAS  Google Scholar 

  • Sommerkamp H, Altwein JE (1988) Prostatakarzinom — Spektrum der kurativen Therapie. Karger, Basel

    Google Scholar 

  • Sommerkamp H, Altwein JE (1989) Lokale Tumorkontrolle — Effizienz kurativer Verfahren. In: Sommerkamp H, Altwein JE (Hrsg) Prostatakarzinom — Spektrum der kurativen Therapie. Karger, Basel, S 322

    Google Scholar 

  • Sonda LP (1991) Second-look prostate resection for incidental carcinoma of the prostate. In: Altwein JE, Faul P, Schneider W (eds) Incidental carcinoma of the prostate. Springer, Berlin Heidelberg New York Tokyo, pp 109–113

    Google Scholar 

  • Stamey TA (1990) Die Rolle des prostataspezifischen Antigens bei der Diagnose und Behandlung des Prostatatadenokarzinoms. Urologe A 29: 52–64

    PubMed  CAS  Google Scholar 

  • Stamey TA, McNeal JE, Freiha FS et al. (1988) Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 139: 1235–1241

    PubMed  CAS  Google Scholar 

  • Stamey TA, Kabalin JN, Ferrari M (1989) Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients. J Urol 141: 1084

    PubMed  CAS  Google Scholar 

  • Stamey TA, Villers AA, McNeal JA et al. (1990) Positive surgical margins at radical prostatectomy: importance of the apical dissection. J Urol 143: 1166–1173

    PubMed  CAS  Google Scholar 

  • Steenbrugge van GJ, Groen M, Bold-de Vried J et al. (1985) Human prostate cancer (PC-82) in nude mice: a model to study androgen regulated tumor growth. In: Schröder FH, Richards B (eds) EORTC GU Group Monograph 2, part A. Liss, New York, pp 23–33

    Google Scholar 

  • Stege R, Lundh B, Tribukait B et al. (1990) DNA ploidy and the direct assay of prostatic acid phosphatase and prostatic specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinoma. J Urol 144: 299–302

    PubMed  CAS  Google Scholar 

  • Stephens RL, Vaughn C, Lane M et al. (1984) Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. Cancer 53: 406–410

    PubMed  CAS  Google Scholar 

  • Suciu S, Sylvester R, Iverson P et al. (1990) Comparability of EORTC and DAPROCA studies in advanced prostate cancer. Cancer 66: 1029–1034

    PubMed  CAS  Google Scholar 

  • Sutton MA, Gibbons RP, Correa RJ Jr (1990) Is deleting the digital rectal examination a good idea? West J Med 155: 43–46

    Google Scholar 

  • Takadu F (1987) Effect of treatment of malignant tumors with recombinant interferon a. Jpn J Cancer Chemother 14: 645–652

    Google Scholar 

  • Tannenbaum M, Tannenbaum S, DeSandis PN et al. (1982) Prognostic significance of nucleolar surface area in prostatic cancer. Urology 19: 546–551

    PubMed  CAS  Google Scholar 

  • Tejada F Eisenberger MA, Broder LA (1977) 5-fluorouracil versus CCNU in the treatment of metastatic prostatic cancer. Cancer Treat Rep 6: 1589–1590

    Google Scholar 

  • Terris MK, McNeal J, Stamey TA (1990) Invasion of the seminal vesicle by prostate cancer: detection with transrectal sonography. AJR 155: 811–815

    PubMed  CAS  Google Scholar 

  • The Leuprolide Study Group (1984) Leuprolide versus diethylstilbestrol for metastatic prostatic cancer. N Engl J Med 311: 1281–1286

    Google Scholar 

  • Thompson IM, Fair WR (1989) Screening for carcinoma of the prostate: efficacy of available screening tests. World J Surg 13: 65–70

    PubMed  CAS  Google Scholar 

  • Tjota A, Zhang JQ, Piedmonte MR, Lee CL (1991) Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases in synergic Dunning rat prostate tumor. J Urol 146: 177–183

    PubMed  CAS  Google Scholar 

  • Tomlinson RL, Currie DP, Boyce WH (1977) Radical prostatectomy: palliation for stage C carcinome of the prostate. J Urol 117: 85–87

    PubMed  CAS  Google Scholar 

  • Torti FM, Aston D, Lum BL (1983) Weekly doxorubicin in endocrine refractory carcinoma of the prostate. J Clin Oncol 1: 477–482

    PubMed  CAS  Google Scholar 

  • Torti FM, Shortliffe LD, Carter SK (1985) A randomized study of doxorubicin versus doxorubicin plus cis-platinum in endocrine unresponsive metastatic prostatic carcinoma. Cancer 56: 2580–2, 586

    Google Scholar 

  • Tribukait B (1987) Flow cytometry in assessing the clinical aggressiveness of genito-urinary neoplasms. World J Urol 5: 108–122

    Google Scholar 

  • Trump DL, Loprinzi CL (1984) Phase II trial of etoposide in advanced prostate cancer. Cancer Treat Rep 68: 1195

    PubMed  CAS  Google Scholar 

  • Tubiana M, Malaise P (1976) Growth rate and cell kinetics in human tumors:. some prognostic and therapeutic implications. In: Symington T, Carter RL (eds) Scientific foundations of oncology. Heinemann, London, pp 126–135

    Google Scholar 

  • Tyrell CJ, Altwein JE, Klippel F et al. (1991) A multicenter randomized trial comparing the LH-RH analogue gosereline acetate alone with flutamide in the treatment of advanced prostate cancer. J Urol 146: 1321–1326

    Google Scholar 

  • Uzbicki RM, Amer RH, Al-Sarraf M (1979) Combination of adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma. Cancer Treat Rep 63: 999–1001

    Google Scholar 

  • Vahlensieck W (1978) Reconstruction of the urethra with a tube from a bladder flap during radical retropubic prostatectomy. In: Rost A, Fiedler U (eds) Proceedings. II. International Symposium on the Treatment of Carcinoma of the Prostate. Hausdruckerei Klinikum Steglitz, Berlin, pp 209–213

    Google Scholar 

  • Vahlensieck W, Jaeger N (1987) Reconstruction of the urethra by tube from a bladder flap during radical retropubic prostatectomy. Prog Clin Biol Res 243 B: 395–398

    Google Scholar 

  • Veronesi A, Zattoni F Frustacci S et al. (1982) Estramustine phosphate (Estracyt) treatment of T3—T4 prostatic carcinoma. Prostate 3: 159–164

    PubMed  CAS  Google Scholar 

  • Voges G, Hohenfellner R (1990) Prostatakarzinom: Keine Behandlung — eine Operation bei klinisch lokalisiertem Tumor? Aktuel Urol 21: 232–233

    Google Scholar 

  • Walsh PC (1987) Radical prostatectomy, preservation of sexual function, cancer control. The controversy. Urol Clin N Am 14: 663–673

    CAS  Google Scholar 

  • Walsh PC, Donker PJ (1982) Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 128: 492–497

    PubMed  CAS  Google Scholar 

  • Walsh PC, Jewett HJ (1980) Radical surgery for prostatic cancer. Cancer 45: 1906–1911

    PubMed  CAS  Google Scholar 

  • Walsh PC, Schlegel PN (1987) Neuroanatomical approach to radical cystoprostatectomy with preservation of sexual function. J Urol 138: 1402–1406

    PubMed  Google Scholar 

  • Walsh PC, Epstein JI, Lowe FC (1987) Potency following radical prostatectomy with wide unilateral excision of the neurovascular bundle. J Urol 138: 823

    PubMed  CAS  Google Scholar 

  • Walther PJ, Williams SD, Troner M, Greco AF, Birch R, Einhorn LH, Southeastern Cancer Study Group (1986) Phase II study of etoposide for carcinoma of the prostate. Cancer Treat Rep 70: 771–772

    Google Scholar 

  • Wang MC, Valenzuela LA, Murphy GP, Chu TM (1979) Purification of a human prostate specific antigen. Invest Urol 17: 159–163

    PubMed  CAS  Google Scholar 

  • Wein AJ (1989) Editorial comment. J Urol 142: 1229

    Google Scholar 

  • Weiss AG, Jackson LA, Carabasi RI (1961) An evaluation of 5-fluorouracil in malignant disease. Ann Intern Med 55: 731–741

    PubMed  CAS  Google Scholar 

  • Weißbach L, Rübben H, Jellinghaus W (1990) Die Chemotherapie des Prostatakarzinoms. In: Nagel R (Hrsg) Aktuelle Standortbestimmung der konservativen Therapie des Prostata-Carcinoms. De Gruyther, Berlin, S 175–190

    Google Scholar 

  • White RD, Paulson DF, Glenn JR (1977) The clinical spectrum of prostate cancer. J Urol 117: 323

    Google Scholar 

  • Whitmore WF (1973) The natural history of prostatic cancer. Cancer 32: 1104

    PubMed  Google Scholar 

  • Whitemore WF, Warker JA, Thompson IM (1991) Expectant management of localized prostatic cancer. Cancer 67: 1091–1096

    Google Scholar 

  • Wilson DW, Harper ME, Jensen RM et al. (1985) A prognostic index for the clinical management of patients with advanced prostatic cancer. Prostate 7: 131–141

    PubMed  CAS  Google Scholar 

  • Wilson JMG (1987) Epidemiology. In: Bruce AW, Trachtenberg J (eds) Adenocarcinoma of the prostate. Springer, Berlin Heidelberg New York, pp 1–28

    Google Scholar 

  • Wilson JMG, Jungner G (1968) Principles and practice for screening for disease. WHO, Genf, Public Health Paper 34

    Google Scholar 

  • Wirth MP (1990) Wertigkeit der Chemotherapie in der Behandlung des fortgeschrittenen Prostatakarzinoms. In: Frohmüller HGW, Wirth MP (Hrsg) Behandlung des fortgeschrittenen Prostatakarzinoms, 14. Springer, Berlin Heidelberg New York Tokyo, S 16–21

    Google Scholar 

  • Wirth MP, Grups J, Frohmüller H (1986) Vergleichende Untersuchungen des prostataspezifischen Antigens und der prostataspezifischen sauren Phosphatase in der Diagnostik und Verlaufskontrolle des Prostata-Carcinoms. Verh Deutsch Ges Urol 4: 75–76

    Google Scholar 

  • Wirth MP, Manseck A, Frohmüller H (1990) Wertigkeit des prostatspezifischen Antigens (PSA) und der prostataspezifischen sauren Phosphatase in der Früherkennung des Prostata-Carcinoms. Urologe A 29: 10

    Google Scholar 

  • Woolf CM (1960) An investigation of the familiar aspects of carcinoma of the prostate. Cancer 13: 739–743

    PubMed  CAS  Google Scholar 

  • Wynder EL, Mabuchi K, Whitmore WF Jr (1971) Epidemiology of cancer of the prostate. Cancer 28: 344

    PubMed  CAS  Google Scholar 

  • Yagoda A, Watson RC, Natale RB, Bartell W, Sogani P, Grabstald H, Whitmore WF (1979) A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamine-dichloride platinum (II). Cancer 44: 1553–1562

    PubMed  CAS  Google Scholar 

  • Yantani R, Chigusa I, Akazaki K et al. (1982) Geographic pathology of latent prostatic carcinoma. Int J Cancer 29: 611–616

    Google Scholar 

  • Yoshimoto J, Tsushima I. Matsumura Y et al. (1985) Phase II study of recombinant human leucocyte A interferon on urogenital cancer patients. Jpn J Cancer Chemother 12: 465–470

    CAS  Google Scholar 

  • Young HH, Kent JR (1968) Plasma testosterone levels in patients with prostatic carcinoma before and after treatment. J Urol 99: 788–792

    PubMed  CAS  Google Scholar 

  • Zagars GK, Eschenbach von AC, Johnson DE, Oswald MJ (1987) Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer 60: 1489

    PubMed  CAS  Google Scholar 

  • Zincke H (1978) Updated experience of management of cancer of the prostate at the Mayo Clinic. In: Rost A, Fiedler U (eds) Proceedings. II. International Symposium on the treatment of carcinoma of the Prostate. Hausdruckerei Klinikum Steglitz, Berlin, pp 57–67

    Google Scholar 

  • Zincke H (1989 a) Extended experience with surgical treatment of stage D adenocarcinomas of prostate. Urology 33 [Suppl]:27–36

    Google Scholar 

  • Zincke H (1989 b) Radikale Prostatektomie bei regionärem Lymphknotenbefall (D1; T0–3 N1–3 MO). In: Sommerkamp H, Altwein JE (Hrsg) Prostatakarzinom — Spektrum der kurativen Therapie. Karger, Basel, S 260–286

    Google Scholar 

  • Zincke H ( 1989 c) Radikale Prostatektomie und adjuvante Therapie beim Adenkarzinom der Prostata. In: Sommerkamp H, Altwein JE (Hrsg) Prostatakarzinom — Spektrum der kurativen Therapie, Karger, Basel, S 244–260

    Google Scholar 

  • Zincke H ( 1989 d) Salvage-Chirurgie bei lokalem Therapieversagen nach Strahlentherapie. In: Sommerkamp H, Altwein JE (Hrsg) Prostatakarzinom — Spektrum der kurativen Therapie, Karger, Basel, S 287

    Google Scholar 

  • Zincke H, Utz DC, Myers RG, Farrow GM, Patterson DE, Furlow WL (1982) Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma of prostate with regional lymphnode involvement. Urology 19: 238–247

    PubMed  CAS  Google Scholar 

  • Zincke H, Utz DC, Taylor WF (1986) Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C cancer: role of adjuvant treatment for residual cancer and in disease progression. J Urol 135: 1199–1205

    PubMed  CAS  Google Scholar 

  • Zincke H, Bergstralh EJ, Larson-Keller JJ et al. (1992) Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment: evidence for favorable survival in patients with DNA diploid tumors. Cancer 70: 311–323

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. J. E. Altwein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Wirth
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Urologischen Klinik und Poliklinik, Medizinische Einrichtungen, Universität-Gesamthochschule Essen, Hufelandstr. 55, 45122, Essen, Deutschland

    Herbert Rübben (Direktor) (Direktor)

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Altwein, J.E., Wirth, M. (1994). Prostatakarzinom. In: Rübben, H. (eds) Uroonkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-22585-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-22585-1_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-22586-8

  • Online ISBN: 978-3-662-22585-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation